« Return to News | R&D Trends

Oncodesign and Ipsen collaborate to battle Parkinson’s target

Monday, January 9, 2012 09:34 AM

Ispen, a global specialty-driven pharmaceutical company, and Oncodesign, a drug discovery company, are collaborating to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson’s disease.

The research collaboration will combine Oncodesign’s Nanocyclix technology for next-generation kinase inhibitors with Ipsen’s expertise in movement disorders. The companies hope research will also provide data for additional uses in other therapeutic areas.

“Today, there is no treatment targeting the underlying pathogenetic mechanism leading to progressive deterioration in [Parkinson’s] patients,” said Claude Bertrand, Ipsen’s executive vice president, R&D and chief scientific officer, noting the importance of the research.

"This agreement allows us to advance our series of attractive LRRK2 inhibitors together with a partner with recognized expertise in CNS research,” said Jan Hoflack, Ph.D., chief scientific officer and leader of Oncodesign's discovery activities. “This is our first drug discovery partnership with a major biopharmaceutical company based on our Nanocyclix technology, validating our ability to identify uniquely potent and selective novel kinase inhibitors for use in Oncology, CNS, and other therapeutic areas."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.